Novartis and Generate:Biomedicines have announced a multi-target collaboration to discover and develop protein therapeutics across multiple disease areas. The collaboration leverages Generate’s generative AI platform, ‘The Generate Platform’, to create potentially first- and best-in-class molecules through AI-based optimisation and de novo generation. The collaboration will combine The Generate Platform, which integrates machine learning with high-throughput […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!